Sangamo Therapeutics, Inc. Stock News

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Research & Technology Louise Wilkie - Head of Global Corporate Communications & Investor Relations Nathalie Dubois-Stringfellow - Senior VP & Chief Development Officer Prathyusha Duraibabu - Senior VP, C...

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathi...

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025.

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist L...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS POSTPONES FIRST QUARTER 2025 CONFERENCE CALL TO LATER THE SAME DAY.